8-K: PDS Biotech Unveils Strong Immunotherapy Data at SITC 2025

PDS Biotechnology announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and immunocytokine PDS01ADC at the 2025 SITC Annual Meeting.

Summary

• PDS Biotechnology presented positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and novel immunocytokine PDS01ADC at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
• PDS0101 combination therapy in 50 patients with advanced HPV16-positive cancers showed strong and broad immune activation, with increases in multiple critical pro-inflammatory cytokines essential for T cell recruitment and potency.
• Quantitative measurements of various immunological proteins in the blood were found to predict clinical benefit with good accuracy for PDS0101.
• PDS01ADC monotherapy promoted the generation of multi-functional natural killer (NK) cells that were associated with induction of a clinical response in advanced treatment-resistant patients with solid tumors.
• Specific types of NK cells associated with effective killing were seen to increase, and NK cells associated with poor anti-tumor response were seen to decrease with PDS01ADC therapy, both linked to an improved clinical response.
• PDS01ADC monotherapy increased the quantity of stem-like memory, CD8 (killer), and CD4 (helper) T cells that had self-replicating properties in patients with advanced solid tumors.
• In 28 patients with advanced solid tumors, increases in stem-like T cells were associated with stabilization of disease.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical and translational data for both PDS0101 and PDS01ADC, demonstrating strong immune activation, predictive biomarkers, NK cell reprogramming, and the generation of durable T cells. These findings validate the company's platforms and support advancement towards commercialization, indicating significant progress in its pipeline.

Positives

• PDS0101 combination therapy demonstrated strong and broad immune activation, including increases in critical pro-inflammatory cytokines, in 50 patients with advanced HPV16-positive cancers.
• Immunological biomarkers were identified that accurately predict clinical benefit for PDS0101 combinations, reinforcing strong clinical activity seen across three Phase 2 trials.
• PDS01ADC monotherapy reprogrammed natural killer (NK) cells towards killer phenotypes, increasing effective killing-associated NK cells and decreasing poor anti-tumor response-associated NK cells, linked to improved clinical response.
• PDS01ADC promoted the generation of self-replicating stem-like memory T cells (CD8 and CD4), enhancing the durability of anti-tumor immunity.
• Increases in stem-like T cells were associated with disease stabilization in 28 patients with advanced solid tumors.
• One rapid oral abstract was recognized among the top 150 abstracts at SITC 2025, indicating high scientific merit.

Risks

• Ability to protect intellectual property rights.
• Anticipated capital requirements, including cash runway, and plans for future equity financings.
• Dependence on additional financing to fund operations and complete development and commercialization of product candidates, with risks that raising such capital may restrict operations or require relinquishing rights.
• Limited operating history in the current line of business, making it difficult to evaluate prospects or the likelihood of successful business plan implementation.
• Timing for conducting clinical trials for PDS0101, PDS01ADC, PDS0103, and other Versamune-based product candidates.
• Future success of clinical trials.
• Successful implementation of research and development programs and collaborations, and the interpretation of their results and findings.
• Success, timing, and cost of ongoing and anticipated clinical trials, including statements regarding response rates, initiation, enrollment pace, completion, futility analyses, presentations, and receipt of interim or preliminary results.
• Ability to fully fund disclosed clinical trials, assuming no material changes to currently projected expenses.
• Statements about understanding product candidates' mechanisms of action and interpretation of preclinical and early clinical results from clinical development programs and collaboration studies.
• Ability to continue as a going concern.
• Other factors, including legislative, regulatory, political, and economic developments not within the company's control.

Future Outlook

PDS Biotech plans to continue advancing PDS0101 in a Phase 3 clinical trial in combination with Keytruda (pembrolizumab) for HPV16-positive recurrent/metastatic head and neck cancer. PDS01ADC is being advanced through NCI-led Phase 2 clinical trials under a CRADA with the NCI for metastatic colorectal cancer, cholangiocarcinoma, biochemically recurrent prostate cancer, and castration-resistant and castration-sensitive prostate cancer. The company aims to leverage these insights to design future studies and combination approaches and supports its regulatory strategy to advance these immunotherapies toward commercialization as efficiently as possible.

Management Comments

• "The data presented at SITC further validate the scientific underpinnings of our immunotherapy platforms and confirm that our development approach is achieving the intended immunological and clinical effects." Frank Bedu-Addo, Ph.D., President and Chief Executive Officer.
• "These findings provide a deeper understanding of how our immunotherapies are generating such promising results in advanced cancers. The ability to measure and model these immune effects enhances confidence in our programs and supports our regulatory strategy to advance these novel, investigational immunotherapies toward commercialization as efficiently as possible for patients with difficult-to-treat cancers." Frank Bedu-Addo, Ph.D., President and Chief Executive Officer.
• "The immune signatures we observed with both PDS0101 and PDS01ADC deepen our understanding of how these therapies generate a powerful anti-tumor immune response. We are seeing broad immune activation, including early natural killer cell responses and expansion of durable, stem-like memory T cells, features that are critical for long-term tumor control." Kirk Shepard, M.D., Chief Medical Officer.
• "The translational data presented at SITC, including early immune biomarker signatures, HPV ctDNA dynamics, and coordinated NK and T cell activation validate our platforms scientifically. These insights will also help us design future studies and combination approaches that fully leverage each therapy’s unique mechanism of action." Kirk Shepard, M.D., Chief Medical Officer.

Industry Context

The positive clinical and translational data for PDS Biotech's immunotherapy platforms, PDS0101 and PDS01ADC, align with the broader industry trend towards developing novel immunotherapies that harness the body's immune system to fight cancer. The focus on specific immune mechanisms, such as NK cell reprogramming and the generation of stem-like memory T cells, represents a significant area of research and development in oncology, aiming for more durable and effective anti-tumor responses in difficult-to-treat cancers.

Stakeholder Impact

• Shareholders: Positive clinical data could lead to increased investor confidence and potential share price appreciation, but future financing needs pose dilution risk.
• Patients: The investigational immunotherapies, PDS0101 and PDS01ADC, show promising results for difficult-to-treat cancers, offering potential new treatment options.
• Employees: Continued positive clinical development supports the company's growth and stability.
• Regulatory Authorities: The data supports the company's regulatory strategy to advance these novel immunotherapies.
• Collaborators (NCI): The positive results from CRADA studies validate the collaboration and its scientific contributions.

Next Steps

• Continue advancing PDS0101 in a Phase 3 clinical trial in combination with Keytruda (pembrolizumab) for HPV16-positive recurrent/metastatic head and neck cancer.
• Advance PDS01ADC via NCI-led Phase 2 clinical trials in metastatic colorectal cancer, cholangiocarcinoma, biochemically recurrent prostate cancer, and castration-resistant and castration-sensitive prostate cancer.
• Design future studies and combination approaches based on the insights gained from the translational data.
• Progress toward future regulatory and clinical milestones.

Key Dates

Recommendation

The filing details highly positive clinical and translational data for PDS Biotech's lead immunotherapy candidates, PDS0101 and PDS01ADC, demonstrating strong immune activation, predictive biomarkers, and durable anti-tumor responses. These results validate the scientific foundation of the company's platforms and support their advancement into pivotal and late-stage clinical trials across multiple significant cancer indications. While future capital raises are noted as a risk, the robust clinical progress significantly de-risks the development pipeline and enhances the long-term commercial potential, making it an attractive investment for growth-oriented portfolios.

Keywords

Immunotherapy, Cancer Treatment, HPV16, PDS0101, PDS01ADC, Clinical Data, SITC 2025, Oncology, Biotechnology, Natural Killer Cells, T Cells, Biomarkers, Head and Neck Cancer, Solid Tumors